Inspire Medical Systems (NYSE: INSP) announces Casey Tansey board retirement
Rhea-AI Filing Summary
Inspire Medical Systems, Inc. reported that Board member Casey M. Tansey has decided to retire from its Board of Directors and the committees on which he serves, effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting of Stockholders. The company states that his decision is not due to any disagreement regarding operations, policies, or practices.
Tansey has served on the Board for more than eighteen years, representing U.S. Venture Partners and leading Inspire’s Series A financing in November 2007. He has been involved through the company’s founding, initial public offering, and subsequent growth. Inspire expects to announce a new director to replace him in the near future.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Retirement effective date: July 30, 2026
Board tenure: more than eighteen years
Series A financing date: November 2007
3 metrics
Retirement effective date
July 30, 2026
Effective date of Casey M. Tansey’s retirement from the Board
Board tenure
more than eighteen years
Length of Casey M. Tansey’s service on the Inspire Board
Series A financing date
November 2007
Date of Series A financing led by Casey M. Tansey representing U.S. Venture Partners
Key Terms
obstructive sleep apnea, neurostimulation technology, EU MDR, PDMA-approved, +1 more
5 terms
obstructive sleep apnea medical
"solutions for patients with obstructive sleep apnea (OSA)"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
neurostimulation technology medical
"Inspire therapy is the first FDA-, EU MDR-, and PDMA-approved neurostimulation technology"
EU MDR regulatory
"the first FDA-, EU MDR-, and PDMA-approved neurostimulation technology"
The EU MDR is the European Union’s set of rules governing the safety, testing and approval of medical devices sold in the EU, replacing older standards with stricter requirements for clinical evidence, traceability and post‑market checks. For investors it matters because the regulation affects how quickly products can reach patients, the cost of compliance and the risk of sales delays or recalls—think of it as a building code that can slow or speed a company’s ability to open new properties.
PDMA-approved regulatory
"the first FDA-, EU MDR-, and PDMA-approved neurostimulation technology"
Series A financing financial
"led Inspire’s Series A financing in November 2007"
A Series A financing is an early formal round of investment in a growing private company where outside investors provide significant capital in exchange for a stake in the business. It matters to investors because it helps set the company's market value, shows that professional backers believe the business can scale, and determines how much ownership current holders keep—similar to bringing in a partner to fund and accelerate a first big expansion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did Inspire Medical Systems (INSP) disclose?
Inspire Medical Systems disclosed that Casey M. Tansey will retire from its Board of Directors, effective July 30, 2026, and will not stand for re-election at the company’s 2027 Annual Meeting of Stockholders.
When does Casey Tansey’s retirement from INSP’s board become effective?
Casey Tansey’s retirement from Inspire Medical Systems’ Board becomes effective on July 30, 2026. Until then, he continues serving on the Board and its committees, after which the company expects to appoint a new director to replace him.
Did Casey Tansey resign from INSP’s board because of a disagreement?
No. Inspire Medical Systems states that Casey Tansey’s decision to retire and not stand for re-election was not the result of any disagreement with the company regarding its operations, policies, or practices.
How long has Casey Tansey served on Inspire Medical Systems’ (INSP) board?
Casey Tansey has served on Inspire Medical Systems’ Board of Directors for more than eighteen years. He first joined after leading the company’s Series A financing in November 2007 while representing U.S. Venture Partners.
Will Inspire Medical Systems (INSP) replace Casey Tansey on the board?
Yes. Inspire Medical Systems states that it expects to announce the appointment of a new director to replace Casey Tansey on the Board of Directors in the near future, following his retirement effective July 30, 2026.
What does Inspire Medical Systems (INSP) do?
Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea, including its FDA-, EU MDR-, and PDMA-approved neurostimulation therapy for moderate to severe cases.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 16, 2026
_________________________
(Exact name of registrant as specified in its charter)
_________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(844 ) 672-4357
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 16, 2026, Casey Tansey, a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of his decision to retire from the Board (and the committees on which he serves) and not stand for re-election at the Company’s 2027 Annual Meeting of Stockholders (the “2027 Annual Meeting”). Mr. Tansey’s retirement will become effective July 30, 2026. Mr. Tansey’s decision to retire and not stand for re-election was not the result of any disagreement with the Company or any matter relating to the Company’s operation, policies or practices.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release of Inspire Medical Systems, Inc., dated July 22, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INSPIRE MEDICAL SYSTEMS, INC. | |||||||||||
| Date: | July 22, 2026 | By: | /s/ Bryan K. Phillips | ||||||||
| Bryan K. Phillips | |||||||||||
| Sr. Vice President, General Counsel and Secretary | |||||||||||
3
Exhibit 99.1
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
MINNEAPOLIS, July 22, 2026 – Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Casey M. Tansey from the Inspire Board after more than eighteen years of service, effective July 30.
“We are thankful for the many contributions Mr. Tansey has made to our Board of Directors over the past eighteen years,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “As one of the first venture investors to recognize the potential impact of Inspire therapy for patients with OSA, Mr. Tansey has provided valuable mentorship, leadership, and perspective throughout the Company’s founding, initial public offering and subsequent growth. We are grateful for his long-standing commitment and wish Mr. Tansey the very best in the future.”
Mr. Tansey represented U.S. Venture Partners and led Inspire’s Series A financing in November 2007 and has served on the Inspire Board of Directors since that time. The Company expects to announce the appointment of a new Director to replace Mr. Tansey in the near future.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR-, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443